Zeiss has now released a video for marketing purposes which features CONVIVO as an integral component of their tumour workflow model. This involves a staged process from diagnosis through to treatment of cancers in the Central Nervous System. Zeiss has all the tools from KINEVO 900 through CONVIVO to radiotherapy. There were 296,851 tumours in the CNS identified in 2018.
https://www.zeiss.com/meditec/int/c/tumor-workflow-video.html
Zeiss are clearly serious in this field and are leading the world. OIL shareholders will be rewarded at some stage but timing is still hard to predict.
Zeiss has now released a video for marketing purposes which...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OIL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.015(6.82%) |
Mkt cap ! $196.3M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $277.1K | 1.171M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 61499 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 150000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| OIL (ASX) Chart |